{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:48:48Z","timestamp":1754153328183,"version":"3.41.2"},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>\n    Zusammenfassung\n    <\/jats:title><jats:p>\n    Das muskelinvasive und metastasierte Urothelkarzinom ist eine heterogene Erkrankung mit breitem morphologischem und molekularem Spektrum. Mit der Novelle der WHO-Klassifikation haben sich einige Ver\u00e4nderungen in der Nomenklatur und Einteilung muskelinvasiver und metastasierter Urothelkarzinome ergeben. Aufgrund zunehmender Individualisierung therapeutischer Optionen gewinnt die korrekte Diagnose morphologischer Varianten des Urothelkarzinoms, die mit spezifischen molekularen Alterationen assoziiert sind, zunehmend an Bedeutung. Die morphologischen Varianten korrelieren zudem mit molekularen Subtypen des Urothelkarzinoms. Dar\u00fcber hinaus sind sowohl morphologische als auch molekulare Subtypen mit immunologischen und anderen molekularen Eigenschaften assoziiert, die z.B. in Form des PD-L1- und des NECTIN-4-Status relevant f\u00fcr moderne Immuntherapien oder Antik\u00f6rper-Drugkonjugate sein k\u00f6nnten. Mit der anstehenden Zulassung von Erdafitinib (FGFR3-Inhibitor) werden in Zukunft auch molekulare Tumorboards f\u00fcr Patienten mit metastasiertem Urothelkarzinom an Bedeutung gewinnen.\n    <\/jats:p>","DOI":"10.1055\/a-2442-4797","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:51:48Z","timestamp":1732733508000},"page":"344-348","source":"Crossref","is-referenced-by-count":0,"title":["Das muskelinvasive und metastasierte Urothelkarzinom aus Sicht der Pathologie"],"prefix":"10.1055","volume":"56","author":[{"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Urologie und Kinderurologie, Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis","family":"Kalogirou","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology, Julius-Maximilians-Universit\u00e4t W\u00fcrzburg Medizinische Fakult\u00e4t, Wurzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"volume-title":"Urinary and male genital tumours. Vol. WHO classification of tumours series, 5th ed.; vol. 8","year":"2022","author":"WHO Classification of Tumours Editorial Board","key":"ref1"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"J Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"A Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.humpath.2018.05.022","article-title":"Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype","volume":"80","author":"U Zinnall","year":"2018","journal-title":"Hum Pathol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/cancers12030763","article-title":"Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype","volume":"12","author":"V Weyerer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.2008.19.0256","article-title":"Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide\/doxorubicin and etoposide\/cisplatin in small-cell urothelial cancer","volume":"27","author":"AO Siefker-Radtke","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/iju.12729","article-title":"Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder","volume":"22","author":"D Kaushik","year":"2015","journal-title":"Int J Urol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.euo.2023.07.011","article-title":"Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes","volume":"7","author":"M Eckstein","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/cancers14071692","article-title":"Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer A Narrative Review","volume":"14","author":"G Sj\u00f6dahl","year":"2022","journal-title":"Cancers (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"T Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"DF Bajorin","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","article-title":"Antibody-drug conjugates \u2013 an emerging class of cancer treatment","volume":"114","author":"N Diamantis","year":"2016","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"PM Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"MJ Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"T Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"27","author":"CE Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"J Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"V Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"N Klumper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"F Mosele","year":"2023","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1158\/1078-0432.CCR-22-3882","article-title":"Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance","volume":"29","author":"DH Aggen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"F Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer","volume":"42","author":"N Klumper","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/1756287216638981","article-title":"Molecular substratification of bladder cancer: moving towards individualized patient management","volume":"8","author":"AP Mitra","year":"2016","journal-title":"Ther Adv Urol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1634\/theoncologist.2016-0195","article-title":"Key Lessons Learned from Moffitt\u2019s Molecular Tumor Board: The Clinical Genomics Action Committee Experience","volume":"22","author":"TC Knepper","year":"2017","journal-title":"Oncologist"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"27145","DOI":"10.18632\/oncotarget.16057","article-title":"Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery","volume":"8","author":"AH Bryce","year":"2017","journal-title":"Oncotarget"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"57845","DOI":"10.18632\/oncotarget.18471","article-title":"Implementation and utilization of the molecular tumor board to guide precision medicine","volume":"8","author":"S Harada","year":"2017","journal-title":"Oncotarget"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"389","author":"Y Loriot","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2442-4797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T23:12:16Z","timestamp":1753225936000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2442-4797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":28,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,8]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2442-4797","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"type":"print","value":"0001-7868"},{"type":"electronic","value":"1438-8820"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}